Significant gene expression differences in histologically “Normal” liver biopsies: Implications for control tissue

Tarik Asselah, Ivan Bièche, Ingrid Laurendeau, Michelle Martinot‐Peignoux, Valerie Paradis, Dominique Vidaud, Dominique‐Charles Valla, Pierre Bedossa, Patrick Marcellin, Michel Vidaud – 9 May 2008 – Gene expression technologies allow the analysis of gene networks whose expression is associated with specific pathological conditions compared with normal tissue. We hypothesized that histologically normal tissue obtained in different ways (percutaneous or surgical liver biopsies), usually used as normal controls in gene expression studies, could have different gene expression patterns.

Statins in liver disease: A molehill, an iceberg, or neither?

Curtis K. Argo, Paola Loria, Stephen H. Caldwell, Amedeo Lonardo – 9 May 2008 – A growing number of chronic liver disease patients, especially those with metabolic syndrome–associated nonalcoholic fatty liver disease or hepatitis C virus–associated dysmetabolic syndrome, will take statins to prevent cardiovascular disease. As a result, clinicians will weigh complex issues raised by the interaction of statins with liver metabolism in these disorders.

Excellent outcome following down‐staging of hepatocellular carcinoma prior to liver transplantation: An intention‐to‐treat analysis

Francis Y. Yao, Robert K. Kerlan, Ryutaro Hirose, Timothy J. Davern, Nathan M. Bass, Sandy Feng, Marion Peters, Norah Terrault, Chris E. Freise, Nancy L. Ascher, John P. Roberts – 9 May 2008 – We previously reported encouraging results of down‐staging of hepatocellular carcinoma (HCC) to meet conventional T2 criteria (one lesion 2–5 cm or two to three lesions <3 cm) for orthotopic liver transplantation (OLT) in 30 patients as a test of concept.

Monocyte chemoattractant protein‐1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes

Sophie Clément, Cristiana Juge‐Aubry, Antonino Sgroi, Stéphanie Conzelmann, Valerio Pazienza, Brigitte Pittet‐Cuenod, Christoph A. Meier, Francesco Negro – 9 May 2008 – For many years, adipose tissue has been mainly considered as an inert reservoir for storing triglycerides. Since the discovery that adipocytes may secrete a variety of bioactive molecules (hormones, chemokines, and cytokines), an endocrine and paracrine role for white adipose tissue (WAT) in the regulation of energy balance and other physiological processes has been established, particularly with regard to brain and muscle.

Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C

Stefan Zeuzem, Eric M. Yoshida, Yves Benhamou, Stephen Pianko, Vincent G. Bain, Daniel Shouval, Robert Flisiak, Vratislav Rehak, Mircea Grigorescu, Kelly Kaita, Patrick W. Cronin, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison – 9 May 2008 – The efficacy and safety of albinterferon alfa‐2b (alb‐IFN), a novel recombinant protein consisting of interferon alfa‐2b genetically fused to human albumin, was evaluated in a phase 2b, open‐label study of patients with genotype 1, chronic hepatitis C.

Nitric oxide promotes caspase‐independent hepatic stellate cell apoptosis through the generation of reactive oxygen species

Daniel A. Langer, Amitava Das, David Semela, Ningling Kang‐Decker, Helen Hendrickson, Steven F. Bronk, Zvonimir S. Katusic, Gregory J. Gores, Vijay H. Shah – 5 May 2008 – Hepatic stellate cells (HSCs) contribute to portal hypertension through multiple mechanisms that include collagen deposition, vasoconstriction, and regulation of sinusoidal structure.

Disturbed hepatic carbohydrate management during high metabolic demand in medium‐chain acyl–CoA dehydrogenase (MCAD)–deficient mice

Hilde Herrema, Terry G. J. Derks, Theo H. van Dijk, Vincent W. Bloks, Albert Gerding, Rick Havinga, Uwe J. F. Tietge, Michael Müller, G. Peter A. Smit, Folkert Kuipers, Dirk‐Jan Reijngoud – 5 May 2008 – Medium‐chain acyl–coenzyme A (CoA) dehydrogenase (MCAD) catalyzes crucial steps in mitochondrial fatty acid oxidation, a process that is of key relevance for maintenance of energy homeostasis, especially during high metabolic demand.

Activation of nuclear factor E2‐related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development

Silke Marhenke, Jutta Lamlé, Laura Elisa Buitrago‐Molina, José Manuel Fernández Cañón, Robert Geffers, Milton Finegold, Michael Sporn, Masayuki Yamamoto, Michael P. Manns, Markus Grompe, Arndt Vogel – 2 May 2008 – In tyrosinemia type 1 (HT1), accumulation of toxic metabolites results in oxidative stress and DNA damage, leading to a high incidence of hepatocellular carcinomas. Nuclear factor erythroid‐2 related factor 2 (Nrf2) is a key transcription factor important for cellular protection against oxidative stress and chemical induced liver damage.

Subscribe to